Sartorius

Industry

Bioprocess equipment, Industrial chemistry

Topics

Synthetic biology platforms & biomanufacturing

Role

Producer — “…rug discovery to commercial manufacturing. Key points: - Mission: Simplify progress in the bio-century by tran…”

Why it is bioeconomy

Sartorius is a major global provider of bioreactors, fermentation equipment, and bioprocessing solutions for the pharmaceutical and biotechnology industries.

Products: Octet® R2 BLI System; Octet® R4 BLI System; Octet® R8 BLI System; Octet® R8e BLI System - NEW; Octet® RH16 BLI System; Octet® RH96 BLI System; Octet® N1 BLI System; Octet® AS BLI System; Octet® BLI GxP Compliance Tools; Octet® BLI Biosensors & Kits

Sites 3

• Göttingen, Germany Sartorius AG
• Aubagne
• Aubagne, France

Production, R&D and other sites from the company's website and automated research; street addresses omitted.

Applications

Biopharmaceutical labs · Chemical labs · Food labs · Academic labs · Life Science Research · Basic Research

Products (website)

Octet® R2 BLI System · Octet® R4 BLI System · Octet® R8 BLI System · Octet® R8e BLI System - NEW · Octet® RH16 BLI System · Octet® RH96 BLI System · Octet® N1 BLI System · Octet® AS BLI System · Octet® BLI GxP Compliance Tools · Octet® BLI Biosensors & Kits · Octet® BLI Automation & Integration · Incucyte® CX3 System

Read from the company's own website: about · products · production · quality · rnd · leadership · contact · sustainability

Subsidiaries: Sartorius Stedim Biotech S.A. (71.5% stake) · Sartorius Lab Holding GmbH (100% stake)

• 2026-06 Latest status: The company acquired the remaining 24% interest in its subsidiary Sartorius CellGenix GmbH in the first half of 2026. ↗ ↗ ↗

Recent news 5

Found by automated search; summaries are machine-written in English. The headline names the company or the summary is about it — check the source before relying on it.

• 2026-10-04 Sartorius stock reports 7.7 percent H1 sales growth ad-hoc-news.de
  Sartorius posted 7.7% organic H1 2026 sales growth with a 30.3% underlying EBITDA margin, signaling solid execution and a favorable margin framework ahead of the Q3 results. The company maintains guidance for 2026 (5–9% sales growth in constant currencies and margin above 30%), …
• 2026-09-16 Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing sartorius.com
  Sartorius is expanding its leadership in bioprocessing by partnering with NIBRT to create a premier training center in Dublin for intensified and fully continuous manufacturing, featuring its end-to-end Pionic platform to train thousands of scientists and engineers annually. The …
• 2026-07-23 Sartorius setzt positive Dynamik fort und wächst weiter profitabel sartorius.com
  Sartorius continues a positive trajectory in H1 2026 with robust, currency-adjusted growth of 7.7% in operative revenue, supported by recurring consumables, and an improved EBITDA margin of 30.3%; the company confirms its full-year 2026 guidance, expecting around 5–9% …
• 2026-05-21 Sartorius opens new competence center for cell and gene therapy components in Freiburg, Germany sartorius.com
  Sartorius is expanding its commitment to cell and gene therapy by opening a new, sustainable competence center in Freiburg, Germany, investing over €140 million to boost GMP-compliant production of quality-critical materials (cytokines, growth factors, media) and nearly doubling …
• 2026-05-21 Sartorius eröffnet neues Kompetenzzentrum für Zell- und Gentherapie ‑Komponenten in Freiburg sartorius.com
  Sartorius eröffnet in Freiburg ein neues Kompetenzzentrum für die Entwicklung und Produktion qualitätskritischer Materialien für Zell- und Gentherapien, investiert über 140 Mio. Euro und verdoppelt die Kapazitäten. Das 18.000 m² große Facility, das vollständig ohne fossile …

Ownership & investors 4

Partners & deals 1

Similar companies

Applikon Biotechnology · Bioengineering AG · BIONET · TECNIC Bioprocess Solutions · Bilfinger Life Science · bbi-biotech GmbH · Kbiotech GmbH · CerCell A/S

Registry identifiers

• WKN: 716 563 (Preference Shares)
• ISIN: DE0007165631 (Preference Shares)
• WKN: 716 560 (Ordinary Shares)
• ISIN: DE0007165607 (Ordinary Shares)

Funding

• Latest round: Post ipo debt · 2026-05-01 · US$ 587.4 M
• Total raised: US$ 3.8 B

From automated research (company websites, filings, a commercial company index); not checked by hand. Registry identifiers: confirm in the official registry.